ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United StatesSILICON VALLEY, CA - December 2, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (“ ABVC ” or the “ Company ”) (
NASDAQ: ABVC) today addressed recent public discussions surrounding attention-deficit/hyperactivity disorder (ADHD) treatment in the United States[1]. As reports raise concerns regarding the increasing trend of psychiatric “polypharmacy”, the use of multiple psychiatric medications over time, ABVC reaffirmed the differentiated safety-focused approach of its plant-based ADHD drug candidate, ABV-1505, which has demonstrated a favorable tolerability profile in early clinical in-house studies with no drug-related serious adverse events reported to date.
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030SILICON VALLEY, CA - November 26, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (“ ABVC ” or the “ Company ”) (
NASDAQ: ABVC) today announced that its wholly owned subsidiary, BioKey (Cayman), Inc. (“ BioKey ”), has strengthened its operational platform and long-term development capacity at its 28,176-square-foot pharmaceutical development and manufacturing facility in Silicon Valley. The site continues to serve as a central component of ABVC’s global chemistry, manufacturing, and controls (“ CMC ”) and U.S.-Asia development strategy.
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already ReceivedSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already ReceivedSILICON VALLEY, CA - November 21, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (“ ABVC ” or the “ Company ”) (
NASDAQ: ABVC) announced today that ForSeeCon Eye Corporation (“ ForSeeCon ”) has made an additional US$250,000 payment under the existing ophthalmic medical device licensing agreement (the “ Licensing Agreement ”). To date, ABVC has received US$816,000 in total payments from ForSeeCon in connection with the Licensing Agreement.
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 MillionSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 MillionSILICON VALLEY, CA - November 18, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) (“ABVC” or the “Company”) today announced that it has received an additional US$240,000 licensing payment from its partner OncoX BioPharma, Inc. (“OncoX”) under their existing licensing agreement.
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025SILICON VALLEY, CA - November 3, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. . (
NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced its financial results for the quarter ended September 30, 2025, and provided an update on recent corporate developments.
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and OncologySILICON VALLEY, CA - October 17, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) (“ABVC” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (CNS) disorders was recently highlighted by Insider Monkey [1] as one of the “Best Biotech Penny Stocks,” to invest in now, recognizing the company’s financial growth and advancing pipeline.
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) ProductionSILICON VALLEY, CA - October 8, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) (“ABVC” or the “Company”) today announced that it has received a US$70,000 licensing payment from its partner, ForSeeCon Eye Corporation (“ForSeeCon”), under their global licensing agreement for Vitargus®, the world’s first biodegradable vitreous substitute. With this latest payment, ForSeeCon has now paid a cumulative total of US$566,000 to ABVC under the agreement, which carries a potential value of up to US$30 million in equity consideration [1] , US$3.5 million in cash licensing payments, plus up to US$60 million in future royalties - representing a total potential value of up to US$93.5 million.
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business ModelSILICON VALLEY, CA - September 19, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. . (
NASDAQ: ABVC) (“ABVC” or the “Company”) today announced that it has received a licensing payment of US$145,950 from OncoX BioPharma, Inc. (“OncoX”) under the terms of the parties’ global licensing agreement. With this latest payment, ABVC has collected a total of US$595,950 from OncoX in Q3 2025, contributing to the Company’s total consolidated licensing revenues from all strategic partners of US$1,275,950 for the third quarter to date across multiple partnerships, including AiBtl BioPharma, ForSeeCon Eye Corporation, and OncoX.
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business ModelSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025SILICON VALLEY, CA - August 29, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) (“ABVC” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (CNS) disorders, today announced that its partner OncoX BioPharma has delivered $450,000 in licensing payments in the third quarter of 2025, including $350,000 received in August . These payments underscore the strength of the companies’ strategic alliance and the growing commercial potential of ABVC’s oncology pipeline.
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing CollaborationSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing CollaborationSilicon Valley, CA - ( NewMediaWire ) - August 27, 2025 - ABVC BioPharma, Inc. (
NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced that one of its subsidiaries, BioLite, Inc., received an additional $230,000 milestone payment from AiBtl BioPharma, Inc. (“AiBtl”) under the strategic licensing agreement for ABV-1504 and ABV-1505, two botanical-derived drug candidates being developed for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD).
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing DealSILICON VALLEY, CA - August 22, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced that it has received an additional $100,000 licensing payment from ForSeeCon Eye Corporation (“ForSeeCon”) under the global licensing agreement covering the Company’s innovative vitreous substitute, Vitargus® .
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing DealSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
